Jialiang Medical (GenLight MedTech) Raises Series C+ for BCI and Neurosurgery Devices

Jialiang Medical Raises Series C+

Jialiang Medical (佳量医疗), rebranded in 2026 to Jialiang Brain Science (杭州佳量脑科学股份有限公司, GenLight MedTech), has raised a Series C+ round. The round included participation from Saizhi Bole Capital and Kuanqiao Hengsong Fund (宽桥恒松). No lead investor was disclosed, and the funding amount was not disclosed.

Company Background

Jialiang Medical is a Hangzhou-based brain-computer interface (BCI) and neurosurgery device company founded in 2020. The company operates a data-driven full-stack BCI platform and maintains dual Hangzhou-Singapore hubs as it pursues FDA and CE registrations.

Technology and Product Stack

The company's portfolio spans several areas:

• BCmod — a closed-loop neuromodulation platform.
• LaserRO — an MRI-guided laser ablation system, described as the first domestically approved brain LITT system, cleared by NMPA in October 2025.
• In-house BCI chips and AI surgical-planning software.
• Epilcure — a closed-loop neurostimulator for drug-resistant epilepsy.

The pipeline covers brain tumors, Parkinson disease, and spinal cord injury.

Regulatory and IP Position

According to the company, it holds four NMPA Class III registration certificates and has 400+ IP filings, including 190+ granted patents. It cooperates with 50+ top-tier hospitals.

Deal Details

• Round type: Series C+
• Amount: Not disclosed
• Currency: CNY
• Date: 2026-09-07
• Lead investor: Not disclosed
• Investors: Saizhi Bole Capital, Kuanqiao Hengsong Fund (宽桥恒松)

Why It Matters

Jialiang Medical sits at the intersection of BCI, neurosurgery, and medical device regulation. Its NMPA Class III registrations and cleared LaserRO system indicate progress through China's regulatory pathway, while its stated FDA and CE pursuits point to international ambitions. The breadth of the stack — from chips and software to implantable neurostimulation — suggests a vertically integrated approach to brain-related therapies.

Acquisition Perspective

For strategic acquirers in medical devices, neurotechnology, or BCI, Jialiang Medical offers a portfolio of approved and pipeline products, a substantial patent estate, and hospital relationships. The Series C+ round, backed by Saizhi Bole Capital and Kuanqiao Hengsong Fund, extends the company's institutional funding history. Diligence would focus on regulatory clearances, clinical adoption, IP strength, and the path to FDA and CE registrations.

Summary

Jialiang Medical (佳量医疗), now Jialiang Brain Science (GenLight MedTech), has raised a Series C+ round with participation from Saizhi Bole Capital and Kuanqiao Hengsong Fund. The Hangzhou-based company develops BCI and neurosurgery devices, including the BCmod neuromodulation platform, the NMPA-cleared LaserRO laser ablation system, in-house BCI chips, AI surgical-planning software, and the Epilcure neurostimulator for drug-resistant epilepsy.